Drug Combination Details
| General Information of the Combination (ID: C27728) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | Erlotinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Phase 1 | [1] | ||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| In-vivo Model | Clinical trial | |||||
| Experimental
Result(s) |
Metformin and EGFR-TKI have a synergistic effect in the treatment of DM2 NSCLC patients harboring EGFR-activating mutations. | |||||
